Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $5.4 million.

  • Pulmonx's Cost of Revenue rose 166.01% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 1944.76%. This contributed to the annual value of $21.8 million for FY2024, which is 2156.45% up from last year.
  • Pulmonx's Cost of Revenue amounted to $5.4 million in Q3 2025, which was up 166.01% from $6.7 million recorded in Q2 2025.
  • Pulmonx's 5-year Cost of Revenue high stood at $6.7 million for Q2 2025, and its period low was $2.6 million during Q1 2021.
  • In the last 5 years, Pulmonx's Cost of Revenue had a median value of $4.5 million in 2023 and averaged $4.5 million.
  • As far as peak fluctuations go, Pulmonx's Cost of Revenue tumbled by 1128.71% in 2021, and later skyrocketed by 4756.92% in 2023.
  • Quarter analysis of 5 years shows Pulmonx's Cost of Revenue stood at $3.5 million in 2021, then increased by 22.68% to $4.2 million in 2022, then rose by 15.02% to $4.9 million in 2023, then grew by 26.59% to $6.2 million in 2024, then decreased by 11.74% to $5.4 million in 2025.
  • Its Cost of Revenue stands at $5.4 million for Q3 2025, versus $6.7 million for Q2 2025 and $6.2 million for Q1 2025.